U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure Richmond, Virginia, July 18, 2023 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company, today announced their selection by the U.S. Department of Defense (DOD) Joint Program...